Bruker Corporation
NASDAQ · us_market
No AI summary generated yet for this ticker.
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Bruker (NASDAQ:BRKR) and the rest of the research tools & consumables stocks fared in Q1.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Bruker (NASDAQ:BRKR) and the rest of the research tools & consumables stocks fared in Q1.
Bruker Corporation recently commissioned its BioSpec 18 Tesla preclinical MRI, the world’s highest-field horizontal-bore MRI system, at the Champalimaud Foundation in Lisbon, enabling ultra-high-resolution MRI and MRSI for advanced cancer and neuroscience research in preclinical models. This system’s ability to probe tissue microstructure and localized metabolism in vivo highlights how Bruker’s high-end imaging platforms are becoming embedded in cutting-edge translational oncology and brain...
Bruker Corporation recently commissioned its BioSpec 18 Tesla preclinical MRI, the world’s highest-field horizontal-bore MRI system, at the Champalimaud Foundation in Lisbon, enabling ultra-high-resolution MRI and MRSI for advanced cancer and neuroscience research in preclinical models. This system’s ability to probe tissue microstructure and localized metabolism in vivo highlights how Bruker’s high-end imaging platforms are becoming embedded in cutting-edge translational oncology and brain...
BILLERICA, Mass., May 26, 2026--Bruker Corporation announced the commissioning of a novel BioSpec™ 18 Tesla preclinical MRI, the world’s highest-field horizontal-bore MRI system, at the Champalimaud Foundation in Lisbon, Portugal. The BioSpec 18T system provides increased spatial resolution and sensitivity, enabling advanced magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI) methods for cancer and neuroscience research, where characterization of tissue microstru
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
World's highest-field MRI system provides leading disease biology research capabilitiesBruker Corporation announced the commissioning of a novel BioSpec™ 18 Tesla preclinical MRI, the world's highest-field
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Why Bruker (BRKR) is on investors’ radar today Bruker (BRKR) has drawn attention after a recent move in its share price, with the stock last closing at US$43.27. That puts fresh focus on how its current valuation lines up with fundamentals. See our latest analysis for Bruker. That latest move comes after a 18.91% 7 day share price return and a 15.11% 30 day share price return, although the share price is still down 10.06% year to date and the 3 year total shareholder return of 39.54% and 5...
Why Bruker (BRKR) is on investors’ radar today Bruker (BRKR) has drawn attention after a recent move in its share price, with the stock last closing at US$43.27. That puts fresh focus on how its current valuation lines up with fundamentals. See our latest analysis for Bruker. That latest move comes after a 18.91% 7 day share price return and a 15.11% 30 day share price return, although the share price is still down 10.06% year to date and the 3 year total shareholder return of 39.54% and 5...
UBS analyst Dan Leonard maintains Bruker (NASDAQ:BRKR) with a Neutral and raises the price target from $40 to $45.
Citigroup analyst Patrick Donnelly maintains Bruker (NASDAQ:BRKR) with a Neutral and raises the price target from $40 to $44.
In addition to the earnings release we issued earlier today, during today's conference call, we will be referencing a slide presentation that can be downloaded from the Events and Presentations section of Bruker's Investor Relations website. Before we begin, I would like to reference Bruker's safe harbor statement, which is shown on Slide 2 of the presentation. During this conference call, we will or may make forward-looking statements regarding future events and the financial and operational performance of the company that involve risks and uncertainties, including those related to our recent acquisitions, geopolitical risks, wars or blockades, market demand, tariffs, currency exchange rates, competitive dynamics or supply chains.
TD Cowen analyst Kyle Boucher maintains Bruker (NASDAQ:BRKR) with a Hold and raises the price target from $43 to $45.
In addition to the earnings release we issued earlier today, during today's conference call, we will be referencing a slide presentation that can be downloaded from the Events and Presentations section of Bruker's Investor Relations website. Before we begin, I would like to reference Bruker's safe harbor statement, which is shown on Slide 2 of the presentation. During this conference call, we will or may make forward-looking statements regarding future events and the financial and operational performance of the company that involve risks and uncertainties, including those related to our recent acquisitions, geopolitical risks, wars or blockades, market demand, tariffs, currency exchange rates, competitive dynamics or supply chains.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 16.10M | $581.60M | 0.03% | Added+5.7% | 2026-03-31 |
| StateStreet | passive | 3.91M | $141.38M | 0.00% | Added+2.0% | 2026-03-31 |
| CapResearch | fundamental | 1.07M | $38.61M | 0.01% | New | 2026-03-31 |
| Citadel | multi-strat | 952.9K | $34.42M | 0.04% | Trimmed-38.6% | 2026-03-31 |
| TwoSigma | quant | 616.0K | $22.25M | 0.02% | Added+46.1% | 2026-03-31 |
| DEShaw | quant | 45.9K | $1.66M | 0.00% | Trimmed-85.5% | 2026-03-31 |
| TRowePrice | fundamental | 2.47M | $89.36K | 0.01% | Added+4.5% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-04upcoming | 0.39 | — | — |
| 2026-05-06 | 0.23 | 0.31 | +34.81% |
| 2026-02-12 | 0.65 | 0.59 | -9.76% |
| 2025-11-03 | 0.32 | 0.45 | +38.75% |
| 2025-08-04 | 0.42 | 0.32 | -23.39% |
| 2025-05-07 | 0.20 | 0.11 | -45.00% |
| 2025-02-13 | 0.74 | 0.76 | +3.24% |
| 2024-11-05 | 0.60 | 0.60 | -0.39% |
| 2024-08-06 | 0.51 | 0.52 | +1.85% |
| 2024-05-02 | 0.46 | 0.53 | +14.05% |
| 2024-02-13 | 0.66 | 0.70 | +5.77% |
| 2023-11-02 | 0.63 | 0.74 | +17.27% |
| 2023-08-03 | 0.49 | 0.50 | +2.73% |
| 2023-05-04 | 0.55 | 0.64 | +16.76% |
| 2023-02-09 | 0.72 | 0.74 | +2.52% |
| 2022-11-03 | 0.56 | 0.66 | +18.61% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BRKR | +60.07% | +49.96% | +25.01% | +60.46% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +57.10% | +54.60% | +28.45% | +47.77% |